ClinicalTrials.gg
TerminatedNCT00493038Updated Nov 7, 2014Results posted

Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis

A Phase 4 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Amoxicillin/Clavulanate in Sinusitis and Bacterial Infections, sponsored by Bayer. Terminated at 34 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-07.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was prematurely terminated due to slow enrollment beyond the planned study timelines.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis

02

Conditions studied

  • Sinusitis
  • Bacterial Infections

Keywords

  • Treatment of acute bacterial rhinosinusitis
03

In context

Sinusitis

256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.

This study's enrollment of 293 is above the median of 60 across 196 interventional studies indexed under Sinusitis.

Browse Sinusitis studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Clinical diagnosis of acute rhinosinusitis with signs and symptoms present for >/= 5-7 days but \< 28 days
  • Clinical diagnosis will be confirmed by nasal endoscopic examination

Exclusion criteria

Exclusion Criteria:

  • History of chronic sinusitis defined as greater than four weeks of continuous symptoms (subject with history of sinus surgery may be included; subjects with recurrent acute sinusitis may be included)
  • Any symptoms that suggest the subject's current illness is allergic rhinitis (e.g. repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis
  • Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses
  • Known immunodeficiency diseases including, but not limited to: neutropenia ( \< 1000/mm3), (HIV) infection (Cluster of differentiation 4 (CD4)+ T-cell count of \< 200/mm3). Note: HIV testing is not required
  • Received systemic antibacterial therapy likely to be effective in the treatment of acute bacterial sinusitis for more than 24 hours within 5/6 days of enrollment
  • Requirement for concomitant systemic antibacterial therapy with agents other than those specified in this protocol
  • Currently receiving topical nasal , unless they have been on a stable dose for > 4 weeks prior to enrollment
  • Requirement for concomitant therapy with systemic corticosteroids
  • Pregnant or breast feeding
  • Of in whom pregnancy cannot be excluded by a negative pregnancy test and who are not using reliable barrier method of
  • Received an drug in the past 30 days
  • Previously enrolled in this study
  • Unable to take oral medication
  • History of allergy to quinolone antibiotics or related compounds and beta-lactams
  • History of tendinopathy associated with quinolones
  • Known to have congenital or sporadic syndromes of corrected for rate (QTc) prolongation or receiving concomitant medication reported to increase the QTc interval (e.g. amiodarone, sotalol, disopyramide, quinidine, procainamide, terfenadine)
  • Uncorrected hypokalemia
  • End stage liver cirrhosis (class C)
  • Severe renal impairment requiring dialysis
  • Diagnosis of rapidly fatal illness with a of less than 6 months
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    Moxifloxacin (Avelox, BAY12-8039)

    Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days

    Drug: Moxifloxacin (Avelox, BAY12-8039)

  • Active comparator
    Amoxicillin/Clavulanate

    Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days

    Drug: Amoxicillin/Clavulanate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Response (Per-protocol Population)

    Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"

    Time frame: At 'Test-of-Cure', Day 1-3 after treatment

Secondary outcomes

  1. Number of Participants With Response (Intent-to-treat Population)

    Number of patients in the population who received at least one dose of study medication whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"

    Time frame: At 'Test-of-Cure', Day 1-3 after treatment

  2. Number of Participants With Response (Per-protocol Population)

    Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 24-30 days after treatment was assessed by the investigator as "continued clinical cure"

    Time frame: End of Follow-up, Day 24-30 after treatment

  3. Number of Participants With Response (Microbiologically Valid Patients)

    Bacteriological Efficacy Rate at the 'Test-of-Cure' visit, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.

    Time frame: At 'Test-of-Cure', Day 1-3 after treatment

  4. Number of Participants With Response (Microbiologically Valid Patients)

    Bacteriological Efficacy Rate at the End of Follow-up period, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.

    Time frame: End of Follow-up, Day 24-30 after treatment

07

Results

Posted Apr 13, 2009
Limitations and caveats
The study was prematurely terminated due to slow enrollment beyond the planned study timelines.

Participant flow

Enrollment started on 13 Feb 2006 and the last study visit occurred on 20 Jan 2008. The study was conducted at 34 active otorhinolaryngology centers in Italy.

Treatment
Participant flow — Treatment
MilestoneMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
Started147146
Randomization147146
Treated with study medication145142
Test-of-cure visit123126
Completed123126
Not completed2420
Withdrew: Adverse event84
Withdrew: Lost to follow-up53
Withdrew: Withdrawal by subject1112
Withdrew: Other01
Follow-up
Participant flow — Follow-up
MilestoneMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
Started123126
Completed122126
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryNumber of Participants With Response (Per-protocol Population)

Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"

Time frame:
At 'Test-of-Cure', Day 1-3 after treatment
Reported as:
Number · participants
Number of Participants With Response (Per-protocol Population)
participantsMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
Number of Participants With Response (Per-protocol Population)119125
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Amoxicillin/Clavulanate · Mean difference (final values): 2.1 · 95% CI -1.9 to 6.2Mean difference denotes the difference of clinical cure rates between the two treatment groups (moxifloxacin minus amoxicillin/clavulanate).
SecondaryNumber of Participants With Response (Intent-to-treat Population)

Number of patients in the population who received at least one dose of study medication whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"

Time frame:
At 'Test-of-Cure', Day 1-3 after treatment
Reported as:
Number · participants
Number of Participants With Response (Intent-to-treat Population)
participantsMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
Number of Participants With Response (Intent-to-treat Population)128127
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Amoxicillin/Clavulanate · Mean difference (final values): -0.5 · 95% CI -7.9 to 6.8
SecondaryNumber of Participants With Response (Per-protocol Population)

Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 24-30 days after treatment was assessed by the investigator as "continued clinical cure"

Time frame:
End of Follow-up, Day 24-30 after treatment
Reported as:
Number · participants
Number of Participants With Response (Per-protocol Population)
participantsMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
Number of Participants With Response (Per-protocol Population)108117
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Amoxicillin/Clavulanate · Mean difference (final values): 1.7 · 95% CI -3.8 to 7.1
SecondaryNumber of Participants With Response (Microbiologically Valid Patients)

Bacteriological Efficacy Rate at the 'Test-of-Cure' visit, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.

Time frame:
At 'Test-of-Cure', Day 1-3 after treatment
Reported as:
Number · Participants
Number of Participants With Response (Microbiologically Valid Patients)
ParticipantsMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
Bacteriological success2125
Failure01
SecondaryNumber of Participants With Response (Microbiologically Valid Patients)

Bacteriological Efficacy Rate at the End of Follow-up period, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.

Time frame:
End of Follow-up, Day 24-30 after treatment
Reported as:
Number · Participants
Number of Participants With Response (Microbiologically Valid Patients)
ParticipantsMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
Bacteriological success1923
Failure00
Missing / Indeterminate23

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moxifloxacin (Avelox, BAY12-8039)—1/145 (0.7%)0/145 (0%)
Amoxicillin/Clavulanate—1/142 (0.7%)0/142 (0%)
Most frequent serious events
Most frequent serious events
EventMoxifloxacin (Avelox, BAY12-8039)Amoxicillin/Clavulanate
SinusitisInfections and infestations0/1451/142
Chest painGeneral disorders1/1450/142

Baseline characteristics

Age, Continuous
Age, Continuous(years)Moxifloxacin (Avelox, BAY12-8039)Amoxicillin/ClavulanateTotal
Mean41.7 ± 13.239.7 ± 13.640.7 ± 13.4
Age, Customized
Age, Customized(participants)Moxifloxacin (Avelox, BAY12-8039)Amoxicillin/ClavulanateTotal
<=18 years000
>18 and <65 years133132265
>=65 years121022
Sex: Female, Male
Sex: Female, Male(Participants)Moxifloxacin (Avelox, BAY12-8039)Amoxicillin/ClavulanateTotal
Female6375138
Male8267149
08

Study locations

34 sites
  • San Benedetto del Tronto, Ascoli Piceno 63039, Italy
  • Esine, Brescia 25040, Italy
  • Lamezia Terme, Catanzaro 88046, Italy
  • Cesena, Forlì 47023, Italy
  • Sestri Ponente, Genova 16154, Italy
  • Monza, Monza-Brianza 20052, Italy
  • Comiso, Ragusa 97013, Italy
  • Bari, 70123, Italy
  • Benevento, 82100, Italy
  • Bergamo, 24128, Italy
  • Bologna, 40138, Italy
  • Bolzano, 39100, Italy
  • Caserta, 81100, Italy
  • Catania, 95123, Italy
  • Catania, 95126, Italy
  • Firenze, 50126, Italy
  • Foggia, 71100, Italy
  • Lecce, 73100, Italy
  • Lecco, 23900, Italy
  • Matera, 75100, Italy
  • Milano, 20122, Italy
  • Milano, 20142, Italy
  • Novara, 28100, Italy
  • Pavia, 27100, Italy
  • Perugia, 06122, Italy
  • Pisa, 56126, Italy
  • Roma, 00135, Italy
  • Roma, 00151, Italy
  • Roma, 00184, Italy
  • Siena, 53100, Italy
  • Torino, 10126, Italy
  • Torino, 10141, Italy
  • Treviso, 31100, Italy
  • Udine, 33100, Italy
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2007
First posted
Jun 27, 2007
Start
Feb 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Apr 13, 2009
Last update
Nov 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00493038
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 27, 2007
Start date
Feb 2006
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Apr 13, 2009
Last update
Nov 7, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion